This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know | The Motley Fool
This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment.

Source: The Motley Fool
This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment.